Koutsoukos K, et al. - In this study, real-life data was presented on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. Everolimus proved to have a favorable safety profile and was active in these patients. The pazopanib–everolimus sequence was mainly offered to patients with adverse prognostic features that seemed to attribute to the short progression-free survival and overall survival, thereby resulting in a modest increase in the combined overall survival (OS) of the population.

Methods

• Researchers reviewed data from the medical charts of mRCC patients from 8 centers in Greece and Spain.
• Second-line everolimus treatment was administered or was continued in all patients after failure of first-line treatment with pazopanib.
• They allowed no other previous therapies.
• The determination of progression-free survival (PFS) was observed as the primary end point.

Results

• This study included 31 patients.
• Of these, 26% indicated performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy.
• Median PFS of 3.48 months (95% CI: 2.37–5.06 months) was observed.
• Observations revealed median overall survival (OS) of 8.9 months (95% CI: 6.47–13.14 months) from everolimus initiation.
• From pazopanib initiation, median OS was 14.78 months (95% CI: 10.54–19.08 months).
• Due to adverse events (AEs), 32% of patients temporarily discontinued everolimus.
• Due to toxicity, 22% of patients discontinued everolimus permanently.
• In this study, the most common toxicities included anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%).
• Moreover, 13 patients (42%) reported 14 AEs (27%) that were graded as 3 or 4.